[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343115-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343115-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-multi-center-international-study-to-evaluate-the-safety-functional-and-oncological-outcomes-of-irreversible-electroporation-for-the-ablation-of-prostate-cancer","A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer","","Irreversible electroporation (IRE) is evaluated for localized prostate cancer to balance oncological control with reduced treatment side effects. In an international prospective observational multi-center registry, men with histologically confirmed prostate cancer received IRE and underwent prostate biopsy at 1 year. Functional outcomes were measured using IPSS and IIEF-5, while safety was graded by CTCAE adverse events. Among 411 patients, urinary/sexual scores showed early changes followed by stabilization and low rates of major adverse events.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-multi-center-international-study-to-evaluate-the-safety-functional-and-oncological-outcomes-of-irreversible-electroporation-for-the-ablation-of-prostate-cancer/343115/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-multi-center-international-study-to-evaluate-the-safety-functional-and-oncological-outcomes-of-irreversible-electroporation-for-the-ablation-of-prostate-cancer/343115.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of this study on irreversible electroporation (IRE) for prostate cancer?","Question",{"text":63,"@type":64},"To evaluate the safety, functional outcomes, and oncological outcomes of IRE ablation in men with localized prostate cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were functional outcomes and safety assessed after IRE?",{"text":68,"@type":64},"Functional outcomes were measured using IPSS and IIEF-5 questionnaires, while safety was graded using CTCAE based on treatment-related adverse events.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding oncological detection and adverse events?",{"text":72,"@type":64},"Clinically significant prostate cancer was detected in 24.1% of patients who underwent repeat biopsy at 12–18 months, and major adverse events (Grade 3 or above) were rare. Adverse event rates were low by 6 months and remained stable through 48 months.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343115,1790462388,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":55,"preview_page_count":33,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Prostate Cancer and Prostatic Diseases [www.nature.com/pcan](www.nature.com/pcan)  \nARTICLE OPEN   \nclinical  \nA multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer  \nKai Zhang 1, Phillip Stricker 2, Martin Löhr3, Michael Stehling4, Michel Suberville5, Olivier Cussenot6, Luca Lunelli 7, Chi-Fai Ng 8, Jeremy Teoh 8, Pilar Laguna9 and Jean de la Rosette 9 ✉  \n© The Author(s) 2024  \n\n| | BACKGROUND: Irreversible electroporation (IRE) is a novel technique to treat localized prostate cancer with the aim of achieving oncological control while reducing related side effects. We present the outcomes of localized prostate cancer treated with IRE from a multi-center prospective registry.\u003Cbr>METHODS: Men with histologically conﬁrmed prostate cancer were recruited to receive IRE. All the patients were proposed for prostate biopsy at 1-year post-IRE ablation. The functional outcomes were measured by the International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5) questionnaires. The safety of IRE was graded by the treatment-related adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) .\u003Cbr>RESULTS: 411 patients were recruited in this study from July 2015 to April 2020 . The median follow-up time was 24 months (IQR 15–36) . 116 patients underwent repeat prostate biopsy during 12–18 months after IRE. Clinically signiﬁcant prostate cancer (Gleason ≥ 3 + 4) was detected in 24.1%(28/116) of the patients; any grade prostate cancers were found in 59.5%(69/116) of the patients. The IPSS score increased signiﬁcantly from 7.1 to 8.2 (p = 0.015) at 3 months but decreased to 6.1 at 6 months (p = 0.017) . Afterwards, the IPSS level remained stable during follow-up. The IIEF-5 score decreased at 3 months from 16.0 to 12.1 (p \u003C 0.001) and then maintained equable afterwards. The rate of AEs was 1.8% at 3 months and then dropped to less than 1% at 6 months and remained stable until 48 months after IRE. Major AEs (Grade 3 or above) were rare.\u003Cbr>CONCLUSION: For men with localized prostate cancer, IRE could achieve good urinary and sexual function outcomes and a reasonable oncological result The real-world data are consistent with earlier studies, including recently published randomized | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | controlled studies. The long-term oncological results need further investigation and follow-up. |  |\n|  | Prostate Cancer and Prostatic Diseases (2024) 27:525–530; [https://doi.org/10.1038/s41391-023-00783-y](https://doi.org/10.1038/s41391-023-00783-y) |  |\n|  |  |  |\n\n.  \nINTRODUCTION  \nRadical treatment for localized prostate cancer often confers a major impact on quality of life [1, 2] . This has led to the development of focal therapy for prostate cancer, aiming to achieve equivalent oncological control whilst improving urinary and erectile function preservation.  \nIrreversible electroporation (IRE) is a novel technique using pulsed high-voltage low-energy direct electric current for tumor ablation. As a non-thermal energy platform, IRE has the advantage of sparing surrounding functional structures, including blood vessels and connective tissue [3, 4] . Histopathological outcomes after IRE show a sharp demarcation between ablated and nonablated tissue, whereas thermal ablation techniques show a  \ntransitional zone of partially damaged tissue due to insufﬁcient temperatures for deﬁnitive ablation [5] .  \nThis study presents the results from a multi-center prospective registry, reporting the IRE ablation therapy for localized prostate cancer patients regarding the side effects, quality of life and oncological control in a short-to mid-term follow-up.  \nPATIENTS AND METHODS Study design  \nThis was an int","cbCaiuAzCboGigr9","https://ap.wps.com/l/cbCaiuAzCboGigr9","pdf",589536,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction\n# Patients and Methods","[{\"question\":\"What is the purpose of this study on irreversible electroporation (IRE) for prostate cancer?\",\"answer\":\"To evaluate the safety, functional outcomes, and oncological outcomes of IRE ablation in men with localized prostate cancer.\"},{\"question\":\"How were functional outcomes and safety assessed after IRE?\",\"answer\":\"Functional outcomes were measured using IPSS and IIEF-5 questionnaires, while safety was graded using CTCAE based on treatment-related adverse events.\"},{\"question\":\"What were the key findings regarding oncological detection and adverse events?\",\"answer\":\"Clinically significant prostate cancer was detected in 24.1% of patients who underwent repeat biopsy at 12–18 months, and major adverse events (Grade 3 or above) were rare. Adverse event rates were low by 6 months and remained stable through 48 months.\"}]","A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer | PDF",1790049958,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/369688d1e982a8708ef572d30a6f633e.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46de0443308213cd137ecfc46b753f1c.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1293d9619f8638d6aa70158c8652be4c.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfecd81331bd249e66658b88e0a6dba1.webp",980,1301]